CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service.

Fountain, Daniel M, Piper, Rory J, Poon, Michael T C, Solomou, Georgios, Brennan, Paul M, Chowdhury, Yasir A, Colombo, Francesca, Elmoslemany, Tarek, Ewbank, Frederick G, Grundy, Paul L, Hasan, Md T, Hilling, Molly, Hutchinson, Peter J, Karabatsou, Konstantina, Kolias, Angelos G, McSorley, Nathan J, Millward, Christopher P, Phang, Isaac, Plaha, Puneet, Price, Stephen J, Rominiyi, Ola, Sage, William, Shumon, Syed, Silva, Ines L, Smith, Stuart J, Surash, Surash, Thomson, Simon, Lau, Jun Y, Watts, Colin and Jenkinson, Michael D CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service. Neuro-oncology advances, 3 (1). vdab014. ISSN 2632-2498. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

[img]
Preview
Text (PDF file format)
vdab014.pdf - Published Version

Download (496kB) | Preview
Official URL: https://academic.oup.com/noa

Abstract

Background

The COVID-19 pandemic has profoundly affected cancer services. Our objective was to determine the effect of the COVID-19 pandemic on decision making and the resulting outcomes for patients with newly diagnosed or recurrent intracranial tumors.

Methods

We performed a multicenter prospective study of all adult patients discussed in weekly neuro-oncology and skull base multidisciplinary team meetings who had a newly diagnosed or recurrent intracranial (excluding pituitary) tumor between 01 April and 31 May 2020. All patients had at least 30-day follow-up data. Descriptive statistical reporting was used.

Results

There were 1357 referrals for newly diagnosed or recurrent intracranial tumors across 15 neuro-oncology centers. Of centers with all intracranial tumors, a change in initial management was reported in 8.6% of cases ( = 104/1210). Decisions to change the management plan reduced over time from a peak of 19% referrals at the start of the study to 0% by the end of the study period. Changes in management were reported in 16% ( = 75/466) of cases previously recommended for surgery and 28% of cases previously recommended for chemotherapy ( = 20/72). The reported SARS-CoV-2 infection rate was similar in surgical and non-surgical patients (2.6% vs. 2.4%, > .9).

Conclusions

Disruption to neuro-oncology services in the UK caused by the COVID-19 pandemic was most marked in the first month, affecting all diagnoses. Patients considered for chemotherapy were most affected. In those recommended surgical treatment this was successfully completed. Longer-term outcome data will evaluate oncological treatments received by these patients and overall survival.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: W Public health. Health statistics. Occupational health. Health education
WL Nervous system. Neurology
WO Surgery
Divisions: Clinical Support > Infectious Diseases
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 04 Jun 2021 14:30
Last Modified: 04 Jun 2021 14:30
URI: http://www.repository.uhblibrary.co.uk/id/eprint/4394

Actions (login required)

View Item View Item